With multiple ADCs now available for use in gynecologic cancers, treatment decision-making incorporates biomarker nuances and raises sequencing questions.
Commentary|Articles|April 7, 2026
Gynecologic Oncologists Preview the Abstracts Set to Drive Conversation at SGO 2026
Author(s)Caroline Seymour
Fact checked by: Kyle Doherty
Read below to hear from Drs Markman and Slomovitz on the sessions and abstracts they’re looking forward to at this year’s SGO Annual Meeting on Women’s Cancer.
Advertisement
Advertisement
Ahead of this year’s
Related to this article
Experts in gynecologic oncology overview top research being presented at the 2026 ESMO Congress.
Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
The opinion supports 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks; a European Commission decision is expected in the coming months.
Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.
Read on to see which data are poised to shape clinical discussions and decision-making in lung cancer at the 2026 ESMO Congress in Madrid, Spain.
Advertisement
Advertisement